Costa rica launches first national psoriasis drug tracking program
NCT ID NCT07448402
Summary
This study is creating a national registry to track the real-world results of two specific psoriasis drugs (guselkumab and risankizumab) in Costa Rica. It will follow 50 patients already receiving these medications as part of their normal care to see how well they control skin and joint symptoms and to monitor for any side effects. The goal is to gather local information to help doctors make better treatment decisions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Caja Costarricense del Seguro Social
San José, Provincia de San José, 40901, Costa Rica
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.